Replies to post #153293 on Biotech Values

[mcbio]

But I will note that a few years ago when EXEL didn't interest me at all, many of the EXEL bulls were forwarding arguments that EXEL has so many drugs in the early pipeline and that any of those could hit for the jackpot! Others can correct me, but for a while EXEL was just accumulating failed early stage candidates left and right.

This might be a variation of the "bird in the hand" proverb, but sometimes the cumulative value of multiple shots on goal is not as large as one hopes.

Absolutely. Quantity means nothing at all if there isn't some quality in the pipeline as well. I personally don't think of ARRY as just having quantity. That data in 1H13 will be key, though, to determining the quality of the pipeline.